

HARMONY



ALLIANCE

# Interoperability between registries and other data sources: the HARMONY Big Data Platform


**Jesús María Hernández Rivas**  
University of Salamanca, Spain  
HARMONY and HARMONY PLUS Coordinator

Joint HMA/EMA multi-stakeholder workshop on Patient Registries | 12<sup>th</sup>-13<sup>th</sup> February 2024  
Session 2: Experience gained, and lessons learnt from initiatives aiming to leverage the use of registries

# BIG DATA FOR  
BLOOD CANCER



# The need for Real-World Data research in Hematological Malignancies (HMs)




- Good quality data used to stay isolated
- HMs are rare diseases, with a very precise diagnosis
- RCT data is not always representative of the whole population

# About the HARMONY Alliance

European Public-Private Partnership for big data in hematology

- The HARMONY Alliance is composed of **HARMONY** and **HARMONY PLUS**
- HARMONY (2017-2023) and HARMONY PLUS (2020-2024) are **IHI funded projects**

The Innovative Health Initiative is a European Public-Private Partnership for health research and innovation between the EU and Europe's life science industries.
- We have built a **community with a wide representation of all stakeholder groups**
- Both projects have clear objectives, with an interest in medicines intended for the **treatment of hematological malignancies**.
- Ultimately, the goal is to increase the application of omics data in clinical practices, **speed up drug development**, access pathways and bench-to-bedside processes



# About the HARMONY Alliance

A 7-year-long history of European Public-Private collaboration



Community of approx.  
**500** professionals



> **140** Data Providers from  
34 countries, 19 being  
European




**9** European Patient  
Organizations, also involved in  
carrying out research



**9** Pharma companies,  
providing in-cash and in-kind  
support, and data



Big Data Platform  
with **165,000** records  
identified in all HMs  
Integrated Data Services



**+100** Databases  
harmonized to OMOP  
common data model



**+30** Collaborative projects,  
comprising research ideas,  
definition of COS, and other  
multi-stakeholder activities




Robust Big Data Platform,  
GDPR-compliant data life cycle,  
and visualization tools




# The HARMONY Big Data Platform is open to receive data from organizations worldwide

Number of cases identified per country




# The HARMONY Big Data Platform is open to receive data from organizations worldwide



Number of cases transferred – per disease

## Number of cases transferred per HM

All the data has been transferred complying with GDPR, applying the necessary technical and organizational measures.



### Databarometer




HARMONY




ALLIANCE

# Big Data Platform




# The HARMONY Platform: towards a mixed model

Established as a Data Lake -> transitioning to a mixed model to seize the advantages of data federation



# The quest for data interoperability



## Mapping to OMOP

The HARMONY Platform uses OMOP data model, terminologies, vocabularies, and coding schemes to standardize the format of the data bases received



## Anonymization

Data undergoes a double-step anonymisation process and is checked by a TTP before entering the HARMONY Platform




## Curation

Each dataset is checked for completeness and accuracy



## Identification of data sources

The HARMONY Platform contains data from national registries, hospitals, study groups, universities, pharmaceutical companies...



## Dissemination

We make sure sure that the results produced by our community not only reach the scientific community, but also the wider public.

## Analytics

The HARMONY Platform counts with a team of analysts that support researchers implement state-of-the-art analysis techniques.



## Visualization

We have developed visualization tools to support the generation of new research project ideas and assess their feasibility with the data that is currently available on the HARMONY Platform.



# The quest for data interoperability

Data Standardisation - OMOP Common Data Model

## Raw data



North America



Southeast Asia



Europe

## OMOPed data



## Data with common

data model


terminologies

vocabularies

coding schemes


# The quest for data interoperability

## Data Standardisation - OMOP Common Data Model



# The quest for data interoperability

## Data Standardisation - OMOP Common Data Model



# Data visualization tools

Check our website to assess the feasibility of conducting a research question in AML and ALL to the HARMONY Platform

Home > Big Data Platform

## Big Data Platform

**From data to the next generation of care**

The HARMONY BigData Platform is a secure, innovative research data ecosystem providing a large data lake and state-of-the-art analytic services. The anonymous patient data sets at the Big Data Platform are collected securely following all legal and ethical requirements, harmonized and then analyzed. The data sets are provided by HARMONY Alliance Partners and Associated Members.

### HARMONY Data Exploration Tool

Over 165,000 blood cancer patient datasets have been identified and 115,000 records are currently available for analysis on the HARMONY Big Data Platform. We developed the Data Exploration Tool where you can now explore data. This new tool is now available for ALL and AML cohorts and will soon be a reality for more Hematological Malignancies. Click on the links below to gain access and start exploring!





[Access to ALL Data Exploration Tool >](#) [Access to AML Data Exploration Tool >](#) [Access to AML Outcome Predictor after CR1 >](#)

Check them here!



# Tools for analysis and production of results

Dashboards to support data analysis have been developed in AML, MM, ALL, MDS, and CML



# Tools to support decision-making

## Individualized prediction of outcomes in AML

The aim of this **online tool** is to create a more accurate risk prediction to easily visualize the likelihood of relapse and help to determine in which patient alloHSCT should be performed in CR1

Machine learning model that provides individualized prediction of outcomes for AML patients aged 18-70 years that were not consolidated with allogeneic transplantation.  
Check inclusion and exclusion criteria of patients included for this analysis.

Age: 18 24 30 36 42 48 54 60 66 70

Gender: FEMALE

AML type: De Novo AML




Cytogenetic Abnormalities: Normal K.

Gene Mutations: DNMT3A<sup>mut</sup> NPM1<sup>mut</sup>

Predict Reset



FEMALE, age = 50, DNMT3A<sup>mut</sup>, NPM1<sup>mut</sup>, Normal K.

Confidence interval of individualized predictions is represented by a box with 10%-90% percentile.



Sensitivity Analysis of Age (RFS at 2 years): potential change on outcome prediction if the patient had a different age at diagnosis.

Sensitivity Analysis of Features (RFS at 2 years): potential change on outcome prediction if the patient presented different genomic alterations. Please note that only the 10 genomic alterations with higher prognostic impact for the patient are represented.



Based on Bayesian Additive Regression Trees




## Unique Value Proposition

Offering **comprehensive services**, being the perfect **interface** and **interlocutor** to connect with over 500 **peers** and diversified **stakeholders** of the **pan-European** and **international hematology community**.




**HARMONY**  
**ALLIANCE FOUNDATION**

Access to **a robust, safe, consolidated, GDPR-compliant, Big Data Platform** with **visualization and analytical tools, algorithms and Artificial Intelligence**



# The HARMONY Platform

## Added Value for each Stakeholder Group



### Clinicians and researchers

- Research questions, study design
- High-tier publications
- Improving clinical outcomes

### Patients

- Patient engagement process
- Consents & anonymisation
- Access to QoL data and possibility to send their own research questions
- Identification of prognostic factors

### Pharma

- Evidence generation when submitting dossiers to HTA agencies
- Generation of historic or synthetic arms for single arm trials/external comparison
- Contextualization of RCT-based evidence package with real-world evidence

### All stakeholders

- Submit research proposals
- Become a member of a dedicated research group that includes skilled data scientists
- Contribute to scientific publications under the umbrella of the HARMON Alliance
- Contribute to improving outcomes for individuals with blood cancer


### Regulators and HTAs

- Critical appraisal of company submissions
- Proper definition of the PICO parameters and the place in therapy
- To explore real-life treatment sequencing over time
- Research and validation of surrogate endpoints
- Support development of external controls to inform decision making



# Lessons learnt

## Barriers to harnessing the full value of health data



### Technical

- Data heterogeneity
- Lack of interoperability
- Unfriendly software & manual processing
- Outdated technology
- Lack of data science skills

### Data Quality

- Relevant data limited
- Endpoint recognition lacking
- Unstructured data not allowed
- Inefficient quality control

### Funding & Sustainability

- Insufficient funding
- Fragmentation of funding
- Complex Access to funding

### Competition

- Misalignment limits data sharing
- Scarce experience with research collaborations
- Very competitive environment

### Legal & Political

- Multiple regulatory frameworks
- Different stakeholders' vision
- Concerns on data privacy

### Governance & Trust

- Lack of clarity for data collection & access
- Complex access: TTP required
- Different interests & incentives among stakeholders
- Complex patient consent
- Need for strong data protection requirements

HARMONY



ALLIANCE

# Uniting the hematology community

Working to produce results that  
improve the lives of patients with  
hematologic malignancies



HARMONY  
ALLIANCE FOUNDATION

HARMONY



ALLIANCE

# Thank you

## Join us in creating the next generation of care for blood cancer patients



[www.harmony-alliance.eu](http://www.harmony-alliance.eu)  
[www.bigdataforbloodcancer.eu](http://www.bigdataforbloodcancer.eu)



@HarmonynetEU  
#bigdataforbloodcancer



HARMONY Alliance  
Public-Private Partnership  
for Big Data in Hematology



Big Data for Blood Cancer